CDTRP 2025 Research Innovation Grant Competition Results

CDTRP is thrilled to announce the results of the CDTRP 2025 Research Innovation Grant Competition, made possible through our partnership with various esteemed organizations. We are proud to showcase all of the exciting projects that have been funded in this year’s competition.

We would like to extend our warmest congratulations to Dr. Megan Levings and Dr. Issac Rosado Sanchez and their team for being awarded the CDTRP Research Innovation Grant sponsored by Takeda. We wish them all the best as they embark on their innovative project!

“Takeda is proud of our ongoing support of the Canadian Donation and Transplantation Research Program’s efforts to further medical research initiatives in organ or tissue donation and transplantation,” said Dr. Andrew Vieira, Vice President, Medical and Scientific Affairs, Takeda Canada. “The work being undertaken by Dr. Megan Levings and Dr. Issac Rosado Sanchez’s project Engineering next-generation CAR Tregs for precision immune tolerance in transplantation is an important step in improving the lives of Canadian transplant patients.”

CDTRP Research Innovation Grant sponsored by Takeda: Dr. Megan Levings and Dr. Issac Rosado Sanchez

Project Title: Engineering next-generation CAR Tregs for precision immune tolerance in transplantation

Main affiliation: University of British Columbia

Theme: 4 – Tailor an Optimal Immune System for Each Patient

Lay Abstract

For people who receive an organ transplant, the biggest challenge is helping their body accept the new organ. Right now, patients have to take strong drugs to stop their immune system from attacking the transplant. These drugs can cause serious side effects, including infections and cancer, and they don’t always prevent rejection in the long run. Our research is looking for a better, safer solution. Instead of using drugs to turn off the immune system, we are developing a type of personalized cell therapy. It uses a kind of immune cell called a regulatory T cell, or Treg, which naturally controls the immune system and prevents it from attacking healthy tissues. Our team has previously developed a way to modify these Tregs giving them a special sensor called a “CAR” that helps them find and protect the transplanted organ. This new project builds on past work and aims to further improve CAR Tregs by using gene editing to: first, program the cells to quietly release a tiny amount of a drug that blocks dangerous immune signals—right where it’s needed, not throughout the body; and second, to remove a molecule (CD40L) that can accidentally trigger harmful immune responses. These improvements aim to make CAR-Treg therapy safer, more effective and more targeted. The ultimate goal is to create a new personalized therapy that helps the body accept a transplanted organ without the need for lifelong medications. If successful, this approach could be used in other diseases, like autoimmune conditions, in the future.